{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997444",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997444_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">Oxytetracycline</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">acenocoumarol</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxytetracycline   increases   the anticoagulant effect of   acenocoumarol .  Manufacturer advises monitor INR .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997445",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997445_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acitretin\" outputclass=\"int-drug\">Acitretin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of benign intracranial hypertension when given with</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acitretin   increases   the risk of benign intracranial hypertension when given with   oxytetracycline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acitretin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997446",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997446_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"alcohol\" outputclass=\"int-drug\">alcohol</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  alcohol  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alcohol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997447",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997447_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"alectinib\" outputclass=\"int-drug\">alectinib</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  alectinib  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alectinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997448",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997448_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alitretinoin\" outputclass=\"int-drug\">Alitretinoin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of benign intracranial hypertension when given with</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alitretinoin   increases   the risk of benign intracranial hypertension when given with   oxytetracycline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alitretinoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997449",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997449_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"antacids\" outputclass=\"int-drug\">antacids</ph> <ph outputclass=\"int-magnitude\">greatly</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 to 3 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   antacids   greatly   decrease   the absorption of   oral   oxytetracycline .  Manufacturer advises separate administration by 2 to 3 hours .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Antacids</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997450",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997450_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"asparaginase\" outputclass=\"int-drug\">asparaginase</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  asparaginase  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asparaginase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997451",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997451_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"atorvastatin\" outputclass=\"int-drug\">atorvastatin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  atorvastatin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atorvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"bedaquiline\" outputclass=\"int-drug\">bedaquiline</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  bedaquiline  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bedaquiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"bismuth\" outputclass=\"int-drug\">Bismuth</ph> <ph outputclass=\"int-magnitude\">greatly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Bismuth   greatly   decreases   the efficacy of   oxytetracycline .  Manufacturer advises separate administration by 2 hours .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bismuth</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 to 3 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   is predicted to   decrease   the absorption of   oxytetracycline .  Manufacturer advises separate administration by 2 to 3 hours .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium carbonate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997455",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997455_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">carbamazepine</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  carbamazepine  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997456",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997456_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"clavulanate\" outputclass=\"int-drug\">clavulanate</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  clavulanate  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clavulanate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997457",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997457_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"crisantaspase\" outputclass=\"int-drug\">crisantaspase</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  crisantaspase  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crisantaspase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997458",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997458_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"dactinomycin\" outputclass=\"int-drug\">dactinomycin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  dactinomycin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dactinomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997459",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997459_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"dantrolene\" outputclass=\"int-drug\">dantrolene</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  dantrolene  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dantrolene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997460",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997460_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"flucloxacillin\" outputclass=\"int-drug\">flucloxacillin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  flucloxacillin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flucloxacillin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">fluconazole</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  fluconazole  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"fluvastatin\" outputclass=\"int-drug\">fluvastatin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  fluvastatin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"iron\" outputclass=\"int-drug\">iron</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/oxytetracycline.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3460\">oxytetracycline</xref></ph> should be taken 2 to 3 hours after iron</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   iron   decreases   the absorption of   oral   oxytetracycline .  Manufacturer advises  oxytetracycline  should be taken 2 to 3 hours after iron .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"isoniazid\" outputclass=\"int-drug\">isoniazid</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  isoniazid  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isoniazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"isotretinoin\" outputclass=\"int-drug\">Isotretinoin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of benign intracranial hypertension when given with</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Isotretinoin   increases   the risk of benign intracranial hypertension when given with   oxytetracycline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isotretinoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">itraconazole</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  itraconazole  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"kaolin\" outputclass=\"int-drug\">kaolin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   kaolin   is predicted to   decrease   the absorption of   oral   oxytetracycline .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Kaolin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"lanthanum\" outputclass=\"int-drug\">lanthanum</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   lanthanum   might   decrease   the absorption of   oral   oxytetracycline .  Manufacturer advises separate administration by 2 hours .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lanthanum</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">leflunomide</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  leflunomide  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"lenalidomide\" outputclass=\"int-drug\">lenalidomide</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  lenalidomide  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997471",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997471_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">Oxytetracycline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of lithium (<ph otherprops=\"lithium carbonate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2337\">lithium carbonate</xref></ph>, <ph otherprops=\"lithium citrate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-citrate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2344\">lithium citrate</xref></ph>) toxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxytetracycline   is predicted to   increase   the risk of lithium ( lithium carbonate ,  lithium citrate ) toxicity when given with   lithium .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997472",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997472_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"lomitapide\" outputclass=\"int-drug\">lomitapide</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  lomitapide  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lomitapide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997473",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997473_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"mercaptopurine\" outputclass=\"int-drug\">mercaptopurine</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  mercaptopurine  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mercaptopurine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997474",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997474_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  methotrexate  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997475",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997475_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"micafungin\" outputclass=\"int-drug\">micafungin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  micafungin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Micafungin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997476",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997476_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"neratinib\" outputclass=\"int-drug\">neratinib</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  neratinib  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Neratinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997477",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997477_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"paracetamol\" outputclass=\"int-drug\">paracetamol</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  paracetamol  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paracetamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997478",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997478_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"pegaspargase\" outputclass=\"int-drug\">pegaspargase</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  pegaspargase  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pegaspargase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997479",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997479_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">Oxytetracycline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"phenindione\" outputclass=\"int-drug\">phenindione</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxytetracycline   is predicted to   increase   the anticoagulant effect of   phenindione .  Manufacturer advises monitor INR .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997480",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997480_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"pravastatin\" outputclass=\"int-drug\">pravastatin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  pravastatin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pravastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997481",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997481_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> <ph outputclass=\"int-substanceQualifier\">(magnesium carbonate-containing forms)</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   quinapril   (magnesium carbonate-containing forms)   might   decrease   the absorption of   oral   oxytetracycline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997482",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997482_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"rosuvastatin\" outputclass=\"int-drug\">rosuvastatin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  rosuvastatin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rosuvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997483",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997483_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"simvastatin\" outputclass=\"int-drug\">simvastatin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  simvastatin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Simvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997484",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997484_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"sotorasib\" outputclass=\"int-drug\">sotorasib</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  sotorasib  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotorasib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997485",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997485_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"streptozocin\" outputclass=\"int-drug\">streptozocin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  streptozocin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptozocin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997486",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997486_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"strontium\" outputclass=\"int-drug\">Strontium</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Strontium   is predicted to   decrease   the absorption of   oxytetracycline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Strontium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997487",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997487_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sucralfate\" outputclass=\"int-drug\">sucralfate</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separating administration</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   sucralfate   might   decrease   the absorption of   oral   oxytetracycline .  Manufacturer advises separating administration .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sucralfate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997488",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997488_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"sulfasalazine\" outputclass=\"int-drug\">sulfasalazine</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  sulfasalazine  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfasalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997489",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997489_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"teriflunomide\" outputclass=\"int-drug\">teriflunomide</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  teriflunomide  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Teriflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997490",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997490_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"tigecycline\" outputclass=\"int-drug\">tigecycline</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  tigecycline  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tigecycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997491",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997491_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"trabectedin\" outputclass=\"int-drug\">trabectedin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  trabectedin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trabectedin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997492",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997492_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tretinoin\" outputclass=\"int-drug\">Tretinoin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of benign intracranial hypertension when given with</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tretinoin   increases   the risk of benign intracranial hypertension when given with   oxytetracycline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tretinoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997493",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997493_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"valproate\" outputclass=\"int-drug\">valproate</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  valproate  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valproate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997494",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997494_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  oxytetracycline  and  vincristine  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vincristine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997495",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997495_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">Oxytetracycline</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"warfarin\" outputclass=\"int-drug\">warfarin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxytetracycline   increases   the anticoagulant effect of   warfarin .  Manufacturer advises monitor INR .    \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997496",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2#bnf_i1643857997496_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"zinc\" outputclass=\"int-drug\">zinc</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-heading-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 to 3 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   zinc   is predicted to   decrease   the absorption of   oxytetracycline .  Manufacturer advises separate administration by 2 to 3 hours .    \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zinc</title>"
					}
				}
			],
			"hasSearchLabel": " Oxytetracycline  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/oxytetracycline-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Oxytetracycline </title>"
			},
			"rdfs:label": "oxytetracycline"
		}
	]
}